DHA derivatives of fish oil as dietary supplements: A nutrition-based drug discovery approach for therapies to prevent metabolic cardiotoxicity

Expert Opinion on Drug Discovery

Volumn 7, Issue 8, 2012, Pages 711-721

  Ma, Yonggang ^a   Lindsey, Merry L ^a   Halade, Ganesh V ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

Cardiovascular disease; Dietary supplement; Docosahexaenoic acid; Eicosapentaenoic acid; Fish oil; Metabolic syndrome; Obesity

Indexed keywords

20 EPOXYDOCOSAPENTAENOIC ACID; ACETYLSALICYLIC ACID; ANTHRACYCLINE; CLOPIDOGREL; CRBM 0244; DOCOSAHEXAENOIC ACID; DOXORUBICIN; FISH OIL; ICOSAPENTAENOIC ACID; LONG CHAIN FATTY ACID; OMEGA 3 FATTY ACID; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; BLEEDING; BLOOD PRESSURE; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; COLLAGEN METABOLISM; DRUG EFFICACY; DRUG PURIFICATION; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; HEART RATE; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; KIDNEY DISEASE; LUPUS VULGARIS; METABOLIC SYNDROME X; NONHUMAN; OBESITY; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; RETINA MACULA DEGENERATION; REVIEW;

ANIMALS; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DRUG DISCOVERY; FISH OILS; HEART DISEASES; HUMANS; NUTRITIONAL STATUS;

EID: 84864369256     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2012.694862     Document Type: Review

References (105)

1. Bang HO, Dyerberg J, Nielsen AB. Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos. Lancet 1971;1(7710):1143-5
2. Dyerberg J, Bang HO. Lipid metabolism, atherogenesis, and haemostasis in Eskimos: The role of the prostaglandin-3 family. Haemostasis 1979;8(3-5):227-33 (Pubitemid 10235812)
3. Dyerberg J, Bang HO, Hjorne N. Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr 1975;28(9):958-66
4. Ruzickova J, Rossmeisl M, Prazak T, et al. Omega-3 PUFA of marine origin limit diet-induced obesity in mice by reducing cellularity of adipose tissue. Lipids 2004;39(12):1177-85
5. Rustan AC, Christiansen EN, Drevon CA. Serum lipids, hepatic glycerolipid metabolism and peroxisomal fatty acid oxidation in rats fed omega-3 and omega-6 fatty acids. Biochem J 1992;283(Pt 2):333-9
6. Mozaffarian D,Wu JH. (n-3) Fatty Acids and Cardiovascular Health: ARE Effects of EPA and DHA Shared or Complementary? J Nutr 2012;142(3):614S-25S
7. Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol 2007;99(6A):35C-43C
8. Fassett RG, Gobe GC, Peake JM, Coombes JS. Omega-3 polyunsaturated fatty acids in the treatment of kidney disease. Am J Kidney Dis 2010;56(4):728-42
9. Fernandes G, Bhattacharya A, Rahman M, et al. Effects of n-3 fatty acids on autoimmunity and osteoporosis. Front Biosci 2008;13:4015-20 (Pubitemid 351599674)
10. Bazan NG, Molina MF, GordonWC. Docosahexaenoic acid signalolipidomics in nutrition: Significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases. Annu Rev Nutr 2011;31:321-51
11. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione Investigators (Gruppo Italianoper lo Studio della Sopravvivenza nell'Infarto Miocardico). Lancet 1999;354(9177):447-55
12. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: Effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011;58(20):2047-67
13. Kromhout D, Bosschieter EB, De Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985;312(19):1205-9 (Pubitemid 15009153)
14. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008;372(9645):1223- 30
15. Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 2009;54(7):585-94
16. Kwak SM, Myung SK, Lee YJ, Seo HG. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: A meta-analysis of randomized, double-blind, Placebo-controlled trials. Arch Intern Med 2012. DOI 10.1001/archinternmed.2012.262; in press
17. Cottin SC, Sanders TA, Hall WL. The differential effects of EPA and DHA on cardiovascular risk factors. Proc Nutr Soc 2011;70(2):215-31
18. Gorjao R, Azevedo-Martins AK, Rodrigues HG, et al. Comparative effects of DHA and EPA on cell function. Pharmacol Ther 2009;122(1):56-64
19. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012. DOI 10.1001/jama.2012.39; in press
20. Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol 2008;8(12):923-34
21. Gonzalez-Periz A, Horrillo R, Ferre N, et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: A role for resolvins and protectins. Faseb J 2009;23(6):1946-57
22. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss: An update of the 1997 American heart association scientific statement on obesity and heart disease from the obesity committee of the council on nutrition, physical activity, and metabolism. Circulation 2006;113(6):898-918
23. Ailhaud G, Guesnet P, Cunnane SC. An emerging risk factor for obesity: Does disequilibrium of polyunsaturated fatty acid metabolism contribute to excessive adipose tissue development? Br J Nutr 2008;100(3):461-70
24. Blasbalg TL, Hibbeln JR, Ramsden CE, et al. Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century. Am J Clin Nutr 2011;93(5):950-62
25. Halade GV, Rahman MM, Williams PJ, Fernandes G. High fat diet-induced animal model of age-associated obesity and osteoporosis. J Nutr Biochem 2010;21:332-7
26. Halade GV, El Jamali A, Williams PJ, et al. Obesity-mediated inflammatory microenvironment stimulates osteoclastogenesis and bone loss in mice. Exp Gerontol 2011;46(1):43-52
27. Alvheim AR, Malde MK, Osei-Hyiaman D, et al. Dietary Linoleic Acid Elevates Endogenous 2-AG and Anandamide and Induces Obesity. Obesity (Silver Spring) 2012. DOI-10.1038/oby.2012.38; in press.
28. Storlien LH, Kraegen EW, Chisholm DJ, et al. Fish oil prevents insulin resistance induced by high-fat feeding in rats. Science 1987;237(4817):885-8 (Pubitemid 17128276)
29. Halade GV, Jin YF, Lindsey ML. Roles of saturated vs. polyunsaturated fat in heart failure survival: Not all fats are created equal. Cardiovasc Res 2012;93(1):4-5
30. Oh DY, Talukdar S, Bae EJ, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010;142(5):687-98
31. Farzaneh-Far R, Harris WS, Garg S, et al. Inverse association of erythrocyte n-3 fatty acid levels with inflammatory biomarkers in patients with stable coronary artery disease: The heart and soul study. Atherosclerosis 2009;205(2):538-43
32. Ferrucci L, Cherubini A, Bandinelli S, et al. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab 2006;91(2):439-46 (Pubitemid 43236907)
33. Rizza S, Tesauro M, Cardillo C, et al. Fish oil supplementation improves endothelial function in normoglycemic offspring of patients with type 2 diabetes. Atherosclerosis 2009;206(2):569-74
34. Damsgaard CT, Lauritzen L, Calder PC, et al. Reduced ex vivo interleukin-6 production by dietary fish oil is not modified by linoleic acid intake in healthy men. J Nutr 2009;139(7):1410-14
35. Trebble T, Arden NK, Stroud MA, et al. Inhibition of tumour necrosis factor-alpha and interleukin 6 production by mononuclear cells following dietary fish-oil supplementation in healthy men and response to antioxidant co-supplementation. Br J Nutr 2003;90(2):405-12 (Pubitemid 36992542)
36. Caughey GE, Mantzioris E, Gibson RA, et al. The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr 1996;63(1):116-22 (Pubitemid 26005735)
37. Bouwens M, Van De Rest O, Dellschaft N, et al. Fish-oil supplementation induces antiinflammatory gene expression profiles in human blood mononuclear cells. Am J Clin Nutr 2009;90(2):415-24
38. Halade GV, Rahman MM, Bhattacharya A, et al. Docosahexaenoic acid-enriched fish oil attenuates kidney disease and prolongs median and maximal life span of autoimmune lupus-prone mice. J Immunol 2010;184:5280-5286.
39. Mori TA, Woodman RJ, Burke V, et al. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med 2003;35(7):772-81 (Pubitemid 37329480)
40. Gu Q, Dillon CF, Burt VL, Gillum RF. Association of hypertension treatment and control with all-cause and cardiovascular disease mortality among US adults with hypertension. Am J Hypertens 2010;23(1):38-45
41. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665
42. Mori TA. Omega-3 fatty acids and hypertension in humans. Clin Exp Pharmacol Physiol 2006;33(9):842-6 (Pubitemid 44215141)
43. Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure? a meta-analysis of controlled trials. Circulation 1993;88(2):523-33 (Pubitemid 23228051)
44. Woodman RJ, Mori TA, Burke V, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr 2002;76(5):1007-15 (Pubitemid 35244671)
45. Nestel P, Shige H, Pomeroy S, et al. The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. Am J Clin Nutr 2002;76(2):326-30 (Pubitemid 34804052)
46. Grimsgaard S, Bonaa KH, Hansen JB, Myhre ES. Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans. Am J Clin Nutr 1998;68(1):52-9 (Pubitemid 28307654)
47. Mori TA, Watts GF, Burke V, et al. Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation 2000;102(11):1264-9
48. Mori TA, Bao DQ, Burke V, et al. Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension 1999;34(2):253-60 (Pubitemid 29409224)
49. Theobald HE, Goodall AH, Sattar N, et al. Low-dose docosahexaenoic acid lowers diastolic blood pressure in middle-aged men and women. J Nutr 2007;137(4):973-8 (Pubitemid 46596896)
50. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004;109(23 Suppl 1):III27-32 (Pubitemid 38786440)
51. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993;362(6423):801-9 (Pubitemid 23132154)
52. De Caterina R, Cybulsky MI, Clinton SK, et al. The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. Arterioscler Thromb 1994;14(11):1829-36
53. Omura M, Kobayashi S, Mizukami Y, et al. Eicosapentaenoic acid (EPA) induces Ca(2+)-independent activation and translocation of endothelial nitric oxide synthase and endothelium-dependent vasorelaxation. FEBS Lett 2001;487(3):361-6 (Pubitemid 32121757)
54. Mark G, Sanders TA. The influence of different amounts of n-3 polyunsaturated fatty acids on bleeding time and in vivo vascular reactivity. Br J Nutr 1994;71(1):43-52 (Pubitemid 24045311)
55. Shimokawa H, Vanhoutte PM. Dietary cod-liver oil improves endothelium-dependent responses in hypercholesterolemic and atherosclerotic porcine coronary arteries. Circulation 1988;78(6):1421-30 (Pubitemid 19004244)
56. Leeson CP, Mann A, Kattenhorn M, et al. Relationship between circulating n-3 fatty acid concentrations and endothelial function in early adulthood. Eur Heart J 2002;23(3):216-22 (Pubitemid 36358243)
57. Chin JP, Gust AP, Nestel PJ, Dart AM. Marine oils dose-dependently inhibit vasoconstriction of forearm resistance vessels in humans. Hypertension 1993;21(1):22-8 (Pubitemid 23006448)
58. Goodfellow J, Bellamy MF, Ramsey MW, et al. Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. J Am Coll Cardiol 2000;35(2):265-70 (Pubitemid 30125512)
59. Tagawa T, Hirooka Y, Shimokawa H, et al. Long-term treatment with eicosapentaenoic acid improves exercise-induced vasodilation in patients with coronary artery disease. Hypertens Res 2002;25(6):823-9 (Pubitemid 36024636)
60. Stirban A, Nandrean S, Gotting C, et al. Effects of n-3 fatty acids on macro- and microvascular function in subjects with type 2 diabetes mellitus. Am J Clin Nutr 2010;91(3):808-13
61. Engler MM, Engler MB, Malloy M, et al. Docosahexaenoic acid restores endothelial function in children with hyperlipidemia: Results from the EARLY study. Int J Clin Pharmacol Ther 2004;42(12):672-9 (Pubitemid 39625126)
62. Okumura T, Fujioka Y, Morimoto S, et al. Eicosapentaenoic acid improves endothelial function in hypertriglyceridemic subjects despite increased lipid oxidizability. Am J Med Sci 2002;324(5):247-53 (Pubitemid 35278769)
63. Kelley DS, Siegel D, Fedor DM, et al. DHA supplementation decreases serum C-reactive protein and other markers of inflammation in hypertriglyceridemic men. J Nutr 2009;139(3):495-501
64. Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature 2008;451(7181):904-13 (Pubitemid 351301745)
65. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350(14):1387-97 (Pubitemid 38419992)
66. Burdge GC, Calder PC. Plasma cytokine response during the postprandial period: A potential causal process in vascular disease? Br J Nutr 2005;93(1):3-9
67. Psota TL, Gebauer SK, Kris-Etherton P. Dietary omega-3 fatty acid intake and cardiovascular risk. Am J Cardiol 2006;98(4A):3i-18i
68. Marik PE, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: A systematic review. Clin Cardiol 2009;32(7):365-72
69. Vrablik M, Prusikova M, Snejdrlova M, Zlatohlavek L. Omega-3 fatty acids and cardiovascular disease risk: Do we understand the relationship? Physiol Res 2009;58(Suppl 1):S19-26
70. Ryan AS, Keske MA, Hoffman JP, Nelson EB. Clinical overview of algal-docosahexaenoic acid: Effects on triglyceride levels and other cardiovascular risk factors. Am J Ther 2009;16(2):183-92
71. Holub BJ. Docosahexaenoic acid (DHA) and cardiovascular disease risk factors. Prostaglandins Leukot Essent Fatty Acids 2009;81(2-3):199-204
72. Mori TA, Burke V, Puddey IB, et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 2000;71(5):1085-94 (Pubitemid 30230554)
73. Kelley DS, Adkins Y. Similarities and differences between the effects of EPA and DHA on markers of atherosclerosis in human subjects. Proc Nutr Soc 2012;71;(in press) 1-10
74. Satoh N, Shimatsu A, Kotani K, et al. Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care 2007;30(1):144-6 (Pubitemid 46061295)
75. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 2007;369(9567):1090-8 (Pubitemid 46483662)
76. Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 2011;108(5):682-90
77. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: Therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 2005;45:657-87 (Pubitemid 40261821)
78. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest 2007;117(3):568-75 (Pubitemid 46348511)
79. Kuwahara F, Kai H, Tokuda K, et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002;106(1):130-5 (Pubitemid 34747453)
80. Leask A. TGFbeta, cardiac fibroblasts, and the fibrotic response. Cardiovasc Res 2007;74(2):207-12 (Pubitemid 46533834)
81. Buxton IL, Duan D. Cyclic GMP/protein kinase G phosphorylation of Smad3 blocks transforming growth factor-beta-induced nuclear Smad translocation: A key antifibrogenic mechanism of atrial natriuretic peptide. Circ Res 2008;102(2):151-3 (Pubitemid 351651117)
82. Chen J, Shearer GC, Chen Q, et al. Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts. Circulation 2011;123(6):584-93
83. Fischer R, Dechend R, Qadri F, et al. Dietary n-3 polyunsaturated fatty acids and direct renin inhibition improve electrical remodeling in a model of high human renin hypertension. Hypertension 2008;51(2):540-6 (Pubitemid 351156445)
84. Medeiros FJ, Mothe CG, Aguila MB, Mandarim-de-Lacerda CA. Long-term intake of edible oils benefits blood pressure and myocardial structure in spontaneously hypertensive rat (SHR) and streptozotocin diabetic SHR. Prostaglandins Other Lipid Mediat 2005;78(1-4):231-48 (Pubitemid 41636846)
85. Ramadeen A, Laurent G, dos Santos CC, et al. n-3 Polyunsaturated fatty acids alter expression of fibrotic and hypertrophic genes in a dog model of atrial cardiomyopathy. Heart Rhythm 2010;7(4):520-8
86. Kitamura K, Shibata R, Tsuji Y, et al. Eicosapentaenoic acid prevents atrial fibrillation associated with heart failure in a rabbit model. Am J Physiol Heart Circ Physiol 2011;300(5):H1814-21
87. Serhan CN, Clish CB, Brannon J, et al. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 2000;192(8):1197-204
88. Serhan CN, Hong S, Gronert K, et al. Resolvins: A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002;196(8):1025-37 (Pubitemid 35231761)
89. Tian H, Lu Y, Sherwood AM, et al. Resolvins E1 and D1 in choroid-retinal endothelial cells and leukocytes: Biosynthesis and mechanisms of anti-inflammatory actions. Invest Ophthalmol Vis Sci 2009;50(8):3613-20
90. Rossmeisl M, Jelenik T, Jilkova Z, et al. Prevention and reversal of obesity and glucose intolerance in mice by DHA derivatives. Obesity (Silver Spring) 2009;17(5):1023-31
91. Tian H, Lu Y, Shah SP, Hong S. 14S,21R-dihydroxydocosahexaenoic acid remedies impaired healing and mesenchymal stem cell functions in diabetic wounds. J Biol Chem 2011;286(6):4443-53
92. Morin C, Fortin S, Cantin AM, Rousseau E. Docosahexaenoic acid derivative prevents inflammation and hyperreactivity in lung: Implication of PKC-Potentiated inhibitory protein for heterotrimeric myosin light chain phosphatase of 17 kD in asthma. Am J Respir Cell Mol Biol 2011;45(2):366-75
93. Hichami A, Morin C, Rousseau E, Khan NA. Diacylglycerol-containing docosahexaenoic acid in acyl chain modulates airway smooth muscle tone. Am J Respir Cell Mol Biol 2005;33(4):378-86 (Pubitemid 41416288)
94. Yamamoto K, Itoh T, Abe D, et al. Identification of putative metabolites of docosahexaenoic acid as potent PPARgamma agonists and antidiabetic agents. Bioorg Med Chem Lett 2005;15(3):517-22
95. Itoh T, Murota I, Yoshikai K, et al. Synthesis of docosahexaenoic acid derivatives designed as novel PPARgamma agonists and antidiabetic agents. Bioorg Med Chem 2006;14(1):98-108 (Pubitemid 41635473)
96. Riad A, Bien S, Gratz M, et al. Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice. Eur J Heart Fail 2008;10(3):233-43
97. Nozaki N, Shishido T, Takeishi Y, Kubota I. Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. Circulation 2004;110(18):2869-74 (Pubitemid 39473611)
98. Yamagami T, Porada CD, Pardini RS, et al. Docosahexaenoic acid induces dose dependent cell death in an early undifferentiated subtype of acute myeloid leukemia cell line. Cancer Biol Ther 2009;8(4):331-7
99. Teng LL, Shao L, Zhao YT, et al. The beneficial effect of n-3 polyunsaturated fatty acids on doxorubicin-induced chronic heart failure in rats. J Int Med Res 2010;38(3):940-8
100. Watson PD, Joy PS, Nkonde C, et al. Comparison of bleeding complications with omega-3 fatty acids + aspirin + clopidogrel-versus-aspirin + clopidogrel in patients with cardiovascular disease. Am J Cardiol 2009;104(8):1052-4
101. Brasky TM, Till C, White E, et al. Serum phospholipid fatty acids and prostate cancer risk: Results from the prostate cancer prevention trial. Am J Epidemiol 2011;173(12):1429-39
102. Woodworth HL, McCaskey SJ, Duriancik DM, et al. Dietary fish oil alters T lymphocyte cell populations and exacerbates disease in a mouse model of inflammatory colitis. Cancer Res 2010;70(20):7960-9
103. Harris WS, Mozaffarian D, Rimm E, et al. Omega-6 fatty acids and risk for cardiovascular disease: A science advisory from the American heart association nutrition subcommittee of the council on nutrition, physical activity, and metabolism; council on cardiovascular nursing; and council on epidemiology and prevention. Circulation 2009;119(6):902-7
104. Park Y, Harris W. EPA, but not DHA, decreases mean platelet volume in normal subjects. Lipids 2002;37(10):941-6 (Pubitemid 36026488)
105. Morin C, Fortin S, Rousseau E. 19,20-EpDPE, a bioactive CYP450 metabolite of DHA monoacyglyceride, decreases Ca (2) sensitivity in human pulmonary arteries. Am J Physiol Heart Circ Physiol 2011;301(4):H1311-18